Hussman Strategic Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Hussman Strategic Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.08M	Sell	84,000 -21,000	-20%	-$500K	0.45%	97
2025 Q4	$2.45M	Sell	105,000 -42,000	-29%	-$936K	0.59%	57
2025 Q3	$2.9M	Hold	147,000	–	–	0.63%	39
2025 Q2	$3.19M	Buy	147,000 +63,000	+75%	+$1.49M	0.73%	40
2025 Q1	$2.04M	Sell	84,000 -21,000	-20%	-$473K	0.49%	80
2024 Q4	$2.19M	Hold	105,000	–	–	0.65%	51
2024 Q3	$2.09M	Hold	105,000	–	–	0.51%	88
2024 Q2	$1.63M	Hold	105,000	–	–	0.45%	99
2024 Q1	$1.67M	Sell	105,000 -52,500	-33%	-$791K	0.39%	101
2023 Q4	$2.65M	Hold	157,500	–	–	0.6%	59
2023 Q3	$1.84M	Buy	157,500 +64,500	+69%	+$863K	0.35%	119
2023 Q2	$1.25M	Hold	93,000	–	–	0.23%	188
2023 Q1	$1.54M	Buy	93,000 +31,000	+50%	+$511K	0.24%	172
2022 Q4	$1.15M	Hold	62,000	–	–	0.19%	187
2022 Q3	$795K	Sell	62,000 -68,000	-52%	-$806K	0.14%	229
2022 Q2	$911K	Buy	130,000 +62,000	+91%	+$455K	0.16%	210
2022 Q1	$564K	Hold	68,000	–	–	0.11%	248
2021 Q4	$460K	Sell	68,000 -56,000	-45%	-$368K	0.1%	256
2021 Q3	$657K	Hold	124,000	–	–	0.14%	210
2021 Q2	$713K	Buy	+124,000	New	+$640K	0.15%	229

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Hussman Strategic Advisors's CPRX Position: Q1 2026 in Review

Hussman Strategic Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 20% in Q1 2026, selling an estimated $500K and leaving 84,000 shares worth $2.08M. The position accounts for 0.45% of the portfolio, ranked #97.

Hussman Strategic Advisors first reported a position in CPRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $3.19M in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Hussman Strategic Advisors held 84,000 shares of Catalyst Pharmaceutical worth $2.08M as of Q1 2026.
Hussman Strategic Advisors sold 21,000 Catalyst Pharmaceutical shares in Q1 2026, an estimated $500K.
Catalyst Pharmaceutical made up 0.45% of Hussman Strategic Advisors's portfolio in Q1 2026, its #97 holding.
Hussman Strategic Advisors first reported a position in Catalyst Pharmaceutical in Q2 2021 and has held it in 20 quarters since.
Hussman Strategic Advisors's Catalyst Pharmaceutical position peaked at $3.19M in Q2 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.